CME: ADHD: Therapeutic updates, best practices, and the role of effective prescribing in the treatment of attention deficit hyperactivity disorder in children
ACCREDITATION EXPIRED: December 31, 2015
Activity Description / Statement of Need:
In this online CME self-learning program:
Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral psychiatric disorder consisting of a combination of hyperactivity, inattention, and impulsivity that affects many aspects of life including school, family, and extracurricular activities. ADHD affects between 3% to 7% of children between the ages of 4 and 17 and has significant implications on the child’s development, health, education, and family situation.
ADHD may be linked to a variety of social and environmental factors, including: conflict in parent-child relationships; maternal smoking; fetal alcohol syndrome; lead poisoning; and meningitis. The exact pathophysiology is unclear. However, there is some evidence of decreased brain volume, which may affect executive functioning needed for prioritizing, decision making, motor control, and awareness of space and time. Alterations in dopaminergic, cholinergic, and serontonergic functions have been documented in ADHD which leads to impairment in the ability to delay gratification, resist distractions, regulate arousal, and focus on tasks that are not interesting.
There is evidence of a wide variability in clinicians’ ability to diagnose ADHD,suggesting opportunities for improvement and a gap in care that might be remedied in the form of continuing education.
Agenda
|
Introduction, disclosures |
|
Epidemiology and risk factors for ADHD
|
|
Symptomology and diagnosis of ADHD
|
|
Treatment in patients with ADHD
|
|
Adherence concerns
|
|
Summary, conclusion, and best practice recap |
Target Audience:
Healthcare professionals specializing in: family medicine, internal medicine, mental health, pediatric neurology and psychiatry, or those who otherwise commonly care for pediatric patients with ADHD or related psychiatric diseases.
This program is supported by an educational grant from Shire Pharmaceuticals and Lundbeck Pharmaceuticals.
Release Date: July 01, 2013 -- Expiration Date: December 31, 2015
Faculty: Floyd Sallee, MD, PhD
Agenda
Learning Objectives
By the end of the session the participant will be able to:
- Describe the challenges associated with the diagnosis of ADHD
- Apply existing diagnostic recommendations and criteria to practice in the management of ADHD.
- Identify treatment modalities currently available for management of ADHD and apply them to patient cases utilizing evidence based medicine.
- Evaluate a treatment plan for a specific patient based on degree of ADHD to optimize safety and efficacy, suggesting modifications for improvement.
- Describe the challenges associated with treating patients with ADHD.
Accreditation
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Floyd Sallee, MD PhD has received grant funding and/or consulting income and/or speaker's bureau income from Shire, Shinogi Pharma, Otsuka Pharma, Nextwave, Purdue Pharma, P2One. He has an equity position in P2One.
Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC.
Commercial Support Disclosure: This program is supported by an educational grant from Shire Pharmaceuticals and Lundbeck Pharmaceuticals.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.